BRD9 and hepatocellular carcinoma: Suppression of the TUFT1/AKT pathway in HCC cells using either TUFT1 shRNA or the AKT phosphorylation inhibitor (MK2206) abrogated the promoting effects of BRD9 on cell growth, metastasis, and EMT.